Atossa Therapeutics Inc (ATOS) Year-End Earnings: A Comprehensive AnalysisGuruFocus • 21 days ago
Atossa Therapeutics Inc (ATOS) Reports Increased Operating Expenses and Advances in Clinical TrialsRelated Stocks: ATOS...
Share to Feed
Fully enrolled two Phase 2 studies with data from both expected in the second half of 2024First patient dosed in new Phase 2 breast cancer prevention studyData from ongoing Phase 2 EVANGELINE study...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
SEATTLE, March 19, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ( Atossa or the Company ), today announced that the pre-menopausal, Estrogen Receptor positive (ER+) / Human...
SEATTLE, March 18, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ( Atossa or the Company ), today announced that on March 15, 2024, the Company received written notice from...
SEATTLE, March 12, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ( Atossa or the Company ), a clinical stage biopharmaceutical company developing innovative medicines in areas...
SEATTLE, March 06, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced today that data from the 40mg pharmacokinetic (PK) run-in cohort of the ongoing Phase 2 EVANGELINE...
Atossa Therapeutics doses first patient with (Z)-endoxifen in Phase 2 breast cancer trial...
SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
Atossa Therapeutics' 'standalone and superior drug' Z-endoxifen for breast cancer seen boosting shares by 300...